Tonix Pharmaceuticals Holding Corp. [NASDAQ: TNXP] stock went on a downward path that fall over -9.15% on Monday, amounting to a one-week price decrease of less than -29.12%. The company report on February 11, 2021 that Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm).
Expands Proprietary Uses of Tonix’s Potentiated Oxytocin for Intranasal Administration.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Disorder Stunts Growth of Newborns and, Paradoxically, Can Cause Excessive Hunger During Childhood and Beyond.
Over the last 12 months, TNXP stock rose by 203.17%. The average equity rating for TNXP stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $429.61 million, with 323.91 million shares outstanding and 156.47 million shares in the current float. Compared to the average trading volume of 39.51M shares, TNXP stock reached a trading volume of 21624528 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Tonix Pharmaceuticals Holding Corp. [TNXP]:
ROTH Capital have made an estimate for Tonix Pharmaceuticals Holding Corp. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 18, 2019. The new note on the price target was released on August 18, 2017, representing the official price target for Tonix Pharmaceuticals Holding Corp. stock. On February 17, 2016, analysts decreased their price target for TNXP shares from 18 to 10.
The Average True Range (ATR) for Tonix Pharmaceuticals Holding Corp. is set at 0.20 The Price to Book ratio for the last quarter was 2.63, with the Price to Cash per share for the same quarter was set at 0.17.
TNXP Stock Performance Analysis:
Tonix Pharmaceuticals Holding Corp. [TNXP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -29.12. With this latest performance, TNXP shares gained by 31.63% in over the last four-week period, additionally plugging by 39.31% over the last 6 months – not to mention a rise of 203.17% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TNXP stock in for the last two-week period is set at 49.80, with the RSI for the last a single of trading hit 42.99, and the three-weeks RSI is set at 53.36 for Tonix Pharmaceuticals Holding Corp. [TNXP]. The present Moving Average for the last 50 days of trading for this stock 0.9871, while it was recorded at 1.5240 for the last single week of trading, and 0.8308 for the last 200 days.
Insight into Tonix Pharmaceuticals Holding Corp. Fundamentals:
Return on Total Capital for TNXP is now -172.42, given the latest momentum, and Return on Invested Capital for the company is -172.99. Return on Equity for this stock declined to -173.02, with Return on Assets sitting at -140.02. When it comes to the capital structure of this company, Tonix Pharmaceuticals Holding Corp. [TNXP] has a Total Debt to Total Equity ratio set at 3.80. Additionally, TNXP Total Debt to Total Capital is recorded at 3.66, with Total Debt to Total Assets ending up at 2.46. Long-Term Debt to Equity for the company is recorded at 0.06, with the Long-Term Debt to Total Capital now at 0.06.
Reflecting on the efficiency of the workforce at the company, Tonix Pharmaceuticals Holding Corp. [TNXP] managed to generate an average of -$1,788,625 per employee.Tonix Pharmaceuticals Holding Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 14.20 and a Current Ratio set at 14.20.
TNXP Stock EPS
With the latest financial reports released by the company, Tonix Pharmaceuticals Holding Corp. posted -2.86/share EPS, while the average EPS was predicted by analysts to be reported at -1.49/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -91.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TNXP.
Tonix Pharmaceuticals Holding Corp. [TNXP] Insider Position Details
There are presently around $10 million, or 3.30% of TNXP stock, in the hands of institutional investors. The top three institutional holders of TNXP stocks are: VANGUARD GROUP INC with ownership of 1,815,839, which is approximately 252.276% of the company’s market cap and around 0.05% of the total institutional ownership; BLACKROCK INC., holding 1,471,654 shares of the stock with an approximate value of $1.9 million in TNXP stocks shares; and GSA CAPITAL PARTNERS LLP, currently with $1.47 million in TNXP stock with ownership of nearly 1344.348% of the company’s market capitalization.
Positions in Tonix Pharmaceuticals Holding Corp. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 23 institutional holders increased their position in Tonix Pharmaceuticals Holding Corp. [NASDAQ:TNXP] by around 3,892,063 shares. Additionally, 10 investors decreased positions by around 347,105 shares, while 16 investors held positions by with 3,466,270 shares. The mentioned changes placed institutional holdings at 7,705,438 shares, according to the latest SEC report filing. TNXP stock had 13 new institutional investments in for a total of 724,582 shares, while 8 institutional investors sold positions of 335,760 shares during the same period.